0QF:F:F-Moderna Inc (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 42.225

Change

-4.63 (-9.88)%

Market Cap

USD 14.82B

Volume

4.51K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-08 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
CSJ:F CSL Limited

+2.46 (+1.44%)

USD 82.25B
CSJA:F CSL LTD SPON.ADR 2

+1.00 (+1.18%)

USD 80.95B
RGO:F Regeneron Pharmaceuticals Inc

-7.80 (-1.10%)

USD 74.41B
1AE:F Argen-X

+16.20 (+2.61%)

USD 36.18B
1AEA:F argenx SE

+10.00 (+1.64%)

USD 36.18B
UNC0:F UCB S.A. UNSP.ADR 1/2

+1.00 (+1.07%)

USD 35.06B
DUL:F Alnylam Pharmaceuticals Inc

+4.40 (+1.98%)

USD 29.18B
22UA:F BioNTech SE

-1.50 (-1.25%)

USD 26.21B
49B:F BeiGene Ltd.

N/A

USD 20.08B
49BA:F BeiGene Ltd

-1.00 (-0.58%)

USD 18.99B

ETFs Containing 0QF:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.18% 78% C+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.18% 78% C+ 90% A-
Trailing 12 Months  
Capital Gain -57.40% 18% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.40% 18% F 7% C-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -6.49% 48% F 26% F
Dividend Return -6.49% 48% F 23% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 56.90% 29% F 20% F
Risk Adjusted Return -11.40% 52% F 31% F
Market Capitalization 14.82B 98% N/A 89% A-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector